20 Future Italian HealthTech and MedTech Leaders

Nelson Advisors
3 hours ago
17 min read

The Italian life sciences ecosystem has entered a period of profound structural transformation, transitioning from a cluster of high-quality specialised manufacturers into a primary engine of European medical innovation. Historically recognised as the fourth-largest medical device market in Europe, Italy is now characterised by a surge in venture capital activity, strategic international partnerships and a regulatory environment that is increasingly favourable to high-growth scale-ups.

The convergence of the National Recovery and Resilience Plan (PNRR), which allocates significant capital to healthcare digitalisation and the emergence of institutional investors such as CDP Venture Capital and Angelini Ventures, has created a fertile ground for "soonicorns" positioned for high-value exits or massive fundraising rounds.

As of early 2026, the Italian market size for medical devices and technology stands at approximately $13.04 Billion, with a robust local production value exceeding $10.3 Billion. However, the real story lies in the shift toward "intelligent" healthcare: surgical robotics, gene therapies, neurotechnology, and AI-driven preventative platforms.

This report identifies 20 companies that represent the vanguard of this shift, each demonstrating the technical defensibility and commercial traction required to attract global strategic acquirers and institutional growth capital.

The Macro-Economic and Regulatory Landscape of Italian Innovation

The resurgence of the Italian healthtech sector is underpinned by a notable rebound in investment volumes. The first half of 2025 recorded a 38.88% increase in startup funding compared to the previous year, with medtech leading all other sectors in terms of closed rounds.

Lombardy remains the central hub, accounting for 44.9% of investment activity, followed by Tuscany and Lazio. This geographical concentration is vital for understanding the "cluster effect," where academic excellence in Milan, Pisa and Rome feeds directly into industrial commercialisation.

Economic Indicator	2023 Value	2024 Estimate	2025 Forecast
Total Local Production (M€)	10,111	10,337	10,800
Total Exports (M€)	6,000	6,300	6,750
Total Market Size (M€)	12,911	13,037	13,600
VC Investment Growth	-10.00%	31.00%	39.00%

The regulatory environment in 2026 is defined by two major pillars: the European Medical Device Regulation (MDR) and the European Health Data Space (EHDS). While the MDR transition has been extended through 2027 or 2028 depending on risk class, Italian companies that have achieved early compliance are finding themselves at a significant competitive advantage.

Furthermore, the EHDS framework is transforming real-world data from an inaccessible asset into a strategic resource, favouring startups that have invested in GDPR-compliant data governance.

1. Medical Microinstruments (MMI): The Standard-Bearer for Surgical Robotics

Medical Microinstruments (MMI) represents the most advanced frontier of Italian medtech. Based in Pisa and Milan, MMI has developed the Symani Surgical System, the only robotic platform specifically engineered for open surgery and microsurgery. The system's core innovation is the "NanoWrist" technology, which provides seven degrees of freedom and a level of tremor filtration and motion scaling that allows surgeons to reconnect vessels as small as 0.3 mm with unprecedented precision.

MMI's growth trajectory is defined by its successful US market entry and its expansion into high-acuity surgical applications. In April 2024, the FDA granted De Novo classification to the Symani system, and by February 2024, the company had closed a $110 Million Series C round led by Fidelity Management & Research Company. Total funding now exceeds $220 Million, positioning MMI as a primary challenger to global robotics incumbents.

Feature	Specification
System Name	Symani Surgical System
Degrees of Freedom	7 (Wristed)
Target Procedures	Microsurgery, Lymphatic surgery, Neurosurgery
Latest Funding	$110M Series C (Feb 2024)
Total Capital Raised	approx $220M
Regulatory Status	FDA De Novo, CE Mark

The strategic value of MMI increased significantly in late 2025 with the completion of the first cases in a neurosurgical clinical trial at the Jacobs Institute. By proving that robotic assistance can be used on the surface of the brain for delicate neurovascular manoeuvers, MMI has opened a massive new addressable market.

The leadership team, headed by CEO Mark Toland, who previously transformed Corindus into a leader in vascular robotics before its acquisition by Siemens Healthineers, brings over 350 years of collective medtech experience, making MMI a prime candidate for a multi-billion dollar IPO or a strategic acquisition in 2026.

2. AAVantgarde Bio: Pioneering Large-Gene Delivery in Ophthalmology

AAVantgarde Bio is a clinical-stage biotechnology company that has solved one of the fundamental limitations of gene therapy: the payload capacity of adeno-associated virus (AAV) vectors. While traditional AAV vectors are limited to approximately $4.7$ kilobases, AAVantgarde’s dual-AAV platforms utilise either DNA recombination (Dual Hybrid) or protein trans-splicing (AAV Intein) to deliver genes that are significantly larger.

In November 2025, the company announced the successful closing of a $141 Million Series B financing round co-led by Schroders Capital, Atlas Venture and Forbion. This round included strategic participation from Amgen Ventures and CDP Venture Capital, reflecting broad confidence in the company's ability to treat inherited retinal diseases (IRDs) that were previously considered "undruggable".

The company's lead programs, AAVB-039 for Stargardt disease and AAVB-081 for Usher syndrome type 1B, address conditions affecting over 20,000 patients in the US and EU. The LUCE-1 Phase 1/2 clinical trial for Usher 1B completed enrollment in January 2026, marking the first time a dual-AAV approach has been tested in the human retina. Under the leadership of CEO Natalia Misciattelli, AAVantgarde is advancing a pipeline that has the potential to redefine the standard of care in genomic medicine, making it a high-priority target for biopharma leaders looking to bolster their gene therapy portfolios.

3. Serenis: Scaling Digital Mental Health Infrastructure

Serenis has emerged as Italy's leading platform for mental and physical wellbeing, achieving a revenue growth profile that rivals the fastest-growing healthtech startups in Europe. From a revenue base of $2 Million in 2022, the company reached $25 Million in 2024 and is currently operating at a run-rate above $40 Million in early 2026. This growth prompted a $12 Million Series A follow-on round in September 2025, co-led by Angelini Ventures and CDP Venture Capital.

The Serenis model is a hybrid of a digital platform and a licensed medical center, employing over 2,500 licensed professionals including psychotherapists, psychiatrists, and nutritionists. Its B2B expansion has been particularly effective, serving over 250 corporate clients such as Nestlé, Satispay, and Leroy Merlin.

Metric	Value (End of 2025)
Professional Network	2,500+
People Supported	170,000+
Therapy Sessions	1.5 Million
Corporate Clients	250+
Revenue Run-Rate	$> €40$M

Silvia Wang, the founder of Serenis, has articulated a vision where mental wellbeing is a "structural, not accessory" element of the workplace. By integrating cutting-edge AI for therapy matching and data-driven outcomes monitoring, Serenis has positioned itself as the dominant digital health infrastructure provider in Italy. Given the consolidation wave in Southern European health services, Serenis is a primary candidate for acquisition by a pan-European healthcare platform or a private equity group seeking to build a regional champion.

4. Resalis Therapeutics: The Orthogonal Approach to Obesity

Resalis Therapeutics is tackling the global obesity epidemic with a mechanism of action that is fundamentally different from current GLP-1 receptor agonists. While GLP-1s primarily work through appetite suppression and can lead to the loss of both fat and lean muscle mass, Resalis’ lead candidate, RES-010, is an antisense oligonucleotide (ASO) that targets miR-22.

The science behind Resalis, emerging from Harvard Medical School and Aalborg University, suggests that miR-22 acts as a "master regulator" of fat metabolism. In pre-clinical models, inhibiting miR-22 resulted in healthy, stable weight loss with a complete preservation of lean mass. Furthermore, RES-010 does not impact appetite; instead, it shifts the body's transcriptome toward a non-obesogenic signature.

Program	Mechanism	Target	Potential Indication
RES-010	Antisense Oligo	miR-22	Obesity, Metabolic disorders
RNA Platform	LNA-DNA mixmer	Non-coding RNA	Liver disease, NASH

Sanofi signaled strong validation of this platform by making a strategic equity investment in Resalis in October 2024. As the obesity market matures and clinicians look for "orthogonal" therapies to combine with or replace appetite suppressants, Resalis stands at the centre of a high-value therapeutic category. The company is headquartered in Turin, Italy and is led by CEO Alessandro Panella and CSO Riccardo Panella, positioning it for a major Series B round or a full acquisition by a metabolic-focused biopharma leader in 2026.

5. Newronika: Next-Generation Adaptive Neuromodulation

Newronika is a pioneer in "closed-loop" deep brain stimulation (DBS), a field that is revolutionizing the treatment of Parkinson's disease and other movement disorders. Its proprietary AlphaDBS system dynamically adjusts electrical stimulation based on real-time neural feedback from the patient's brain, a significant improvement over conventional DBS devices that deliver a fixed, continuous pulse.

In March 2025, Newronika received the CE Mark for AlphaDBS, enabling its commercial launch in Europe. This milestone was followed by a €13.6 Million Series B round led by Fondazione ENEA Tech e Biomedical and the receipt of an Investigational Device Exemption (IDE) from the FDA to initiate pivotal clinical trials in the United States.

The adaptive approach of AlphaDBS has been shown to improve symptom control while reducing side effects and the need for manual reprogramming by neurologists. By integrating real-time neural data and machine learning into an implantable device, Newronika has built a high-barrier technology platform. The company is a spin-off of the University of Milan and is led by CEO Lorenzo Rossi, making it a key acquisition target for major neuro-modulation players like Medtronic or Boston Scientific as they look to defend their market share against intelligent competitors.

6. Tensive: Regenerative Scaffolds for Breast Reconstruction

Tensive is a clinical-stage medical device company that has developed a biomimetic scaffold, REGENERA, designed to transform breast reconstruction after lumpectomy. The technology uses a bio-resorbable polymeric matrix that resembles a sponge; once implanted, it allows the patient’s own healthy tissue to regrow in the area of the surgically removed tumour.

Top-line results from Tensive's pivotal trial, released in January 2026, confirmed that REGENERA met its primary safety endpoint and demonstrated high levels of surgeon and patient satisfaction. The scaffold does not interfere with follow-up imaging, which is a critical requirement for cancer patients monitoring for potential recurrence.

Product	Technology	Regulatory Milestone	Market Focus
REGENERA	Bioresorbable Scaffold	CE Mark Expected 2027	Breast reconstruction
SOFTAG	Precision Marking	FDA/CE Path	Tissue marking, radiotherapy

With $23 million raised to date and a clear path toward European and US regulatory approvals in 2027, Tensive is positioned for a substantial growth-stage financing round in 2026. The company addresses a massive care gap: approximately $1.6 Million women per year do not receive breast reconstruction after lumpectomy due to a lack of viable options. Tensive, led by CEO Sanjay Kakkar, is a prime target for companies in the medical aesthetics and oncology sectors.

7. InnovHeart: The Trans-Septal Leap in TMVR

InnovHeart is developing the Saturn Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) system to treat patients with severe symptomatic mitral regurgitation. The mitral valve market is one of the most significant and technically challenging segments in cardiology, attracting billions in investment from global medtech leaders.

The Saturn system is designed for a trans-septal approach, which is significantly less invasive than the older trans-apical methods. InnovHeart is currently conducting the CASSINI-EU pilot trial at six investigational sites in Europe to evaluate the safety and performance of the device. Estimated primary completion for these studies is set for late 2025 and 2026.

The company is led by Chairman Keith Dawkins, a former Global Chief Medical Officer at Boston Scientific, and is backed by prominent investors such as Panakès Partners and XGEN Venture. InnovHeart’s ability to successfully execute a trans-septal TMVR procedure positions it as a high-value acquisition target for companies looking to complete their structural heart portfolios, such as Abbott or Edwards Life Sciences.

8. Sibylla Biotech: Unlocking the "Undruggable" through Protein Folding

Sibylla Biotech has developed a unique drug discovery platform based on Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT). Instead of targeting the final structure of a protein, Sibylla targets the protein during the folding process, allowing them to degrade "un druggable" proteins that are central to diseases such as cancer and neurological disorders.

In May 2025, Sibylla appointed Dieter Weinand, the former CEO of Bayer Pharmaceuticals, as Chairman of its Board of Directors. This appointment, combined with existing drug discovery collaborations with Ono Pharmaceutical and Takeda, signals that Sibylla’s technology has reached a high level of industry validation.

Sibylla raised $23 Million in a Series A round in 2022 and is expected to pursue a significant Series B in 2026 to advance its internal pipeline of folding interference small molecules.

As biopharma shifts toward more targeted protein degradation strategies, Sibylla's ability to unlock previously inaccessible targets makes it an essential partner or acquisition target for large-cap pharmaceutical companies.

9. Diadem: Early Prediction of Alzheimer's Progression

Diadem is at the forefront of the revolution in blood-based biomarkers for neurodegenerative diseases. Its AlzoSure Predict prognostic test utilises a p53-specific antibody to identify patients who will progress to Alzheimer’s disease up to six years before symptoms occur.

The market for Alzheimer’s diagnostics is expanding rapidly, with a projected CAGR of $17.37\%$ through 2033, driven by the recent FDA approval of anti-amyloid monoclonal antibodies like lecanemab. Early diagnosis is critical because these therapies are most effective in the prodromal or mild symptomatic stages of the disease.

Diadem has already received a Breakthrough Device Designation from the FDA and CE-IVD certification for AlzoSure Predict. Under the leadership of CEO Michael Rasche, Diadem is positioned to become a key triage tool in dementia care pathways, reducing the need for invasive lumbar punctures and expensive PET scans. The company is a prime candidate for a strategic partnership with global laboratory networks or diagnostic imaging leaders such as Roche or Siemens Healthineers.

10. BionIT Labs: The Bionic Revolution in Upper Limb Prosthetics

BionIT Labs, based in Soleto, Italy, has disrupted the bionics market with Adam’s Hand, a multi-articulating prosthetic hand that uses a single motor to drive all five fingers. This "fully-adaptive grip" technology allows the hand to automatically adapt its shape to the object being grasped, providing the versatility of much more expensive multi-motor devices at a fraction of the weight and cost.

In July 2024, BionIT Labs received PDAC approval under code L6880, making Adam’s Hand eligible for reimbursement through Medicare and Medicaid in the United States. This was followed by FDA registration for its Wave Electrodes in January 2025.

Regulatory Body	Status	Date
PDAC (Medicare)	Code L6880 Assigned	July 2024
FDA	Wave Electrode Registration	January 2025
ISO 13485	Quality System Certified	Current

The US is the largest market for prosthetics globally, and BionIT Labs has established a North American team with decades of experience to support its commercial rollout. As a high-growth company in the assistive technology space with a proven reimbursement pathway, BionIT Labs is positioned for a significant fundraising round or acquisition by an orthotics and prosthetics (O&P) industry leader in 2026.

11. Echolight: Radiation-Free Bone Densitometry

Echolight is transforming the diagnosis of osteoporosis with its Radiofrequency Echographic Multi Spectrometry (REMS) technology. Unlike the standard Dual-energy X-ray absorptiometry (DXA), which uses ionising radiation and is often limited to specialised hospital settings, REMS is a non-ionising, ultrasound-based approach that can be used at the point of care.

REMS provides accurate bone mineral density (BMD) values and a "Fragility Score" that estimates fracture risk independently of BMD. A 2025 study in the US confirmed that widespread REMS implementation could save 30,000 life-years and prevent 100,000 fractures over a lifetime.

The bone densitometry market is shifting toward portable, AI-ready devices, and Echolight is well-positioned with a sales network of over 40 distributors and hundreds of clinical customers worldwide. Echolight, a spin-off of the Italian National Research Council, has already secured FDA clearance and the CE mark, making it a highly attractive target for diagnostic equipment manufacturers looking to expand their osteoporosis screening capabilities.

12. Altheia Science: Curative Gene Therapy for Autoimmune Diseases

Altheia Science is a gene therapy company targeting the root causes of autoimmune diseases, with its most advanced program, IMMUNOSTEM, focused on Type 1 Diabetes (T1D). The therapy involves collecting a patient’s own hematopoietic stem and progenitor cells (HSPCs), modifying them ex vivo with a lentiviral vector to express PD-L1, and re-injecting them into the patient.

The goal of IMMUNOSTEM is to restore immune tolerance and protect the remaining pancreatic $\beta$-cells from autoimmune destruction. In August 2025, Altheia initiated a Phase I/II clinical trial (IMMUNOSTEM) to evaluate the safety and efficacy of the treatment in newly diagnosed T1D patients.

Clinical Trial	NCT06938334 (IMMUNOSTEM)
Target Population	Adults 18-40, Recently diagnosed T1D
Primary Endpoint	Safety, $\beta$-cell function (C-peptide)
Estimated Completion	August 2029
Mechanism	PD-L1 overexpression in HSPCs

The company's research has also demonstrated clinical benefits in pre-clinical models of multiple sclerosis, suggesting that its "immune-regulatory" platform has broad applicability in the autoimmune space. Given the significant unmet need for curative T1D treatments, Altheia Science is a high-conviction candidate for a large Series B funding round or a strategic partnership with a global cell and gene therapy leader.

13. Wise Srl: Flexible Electrodes for Minimally Invasive Neurostimulation

Wise Srl, based in Milan and Berlin, is developing a new class of flexible and stretchable electrodes for neuro-stimulation. Its first product aimed at the spinal cord stimulation (SCS) market is the "Heron" lead, a multicolumn lead that can be implanted percutaneously.

Traditional SCS paddle leads require a laminectomy, a major surgical procedure that involves removing part of a vertebra.The Heron lead aims to provide the performance of a paddle lead with the ease of a percutaneous lead, conforming to the dura mater within the epidural space.

The company's core technology, Supersonic Cluster Beam Implantation (SCBI), allows for the fabrication of complex microelectronic circuits on stretchable elastomers. This ensures that the electrodes can maintain their electrical performance even after extensive cycles of bending and stretching. Wise Srl raised a seed round in 2013 and has since been developing its clinical evidence base. As the SCS market moves toward more durable and less invasive systems to reduce re-operation rates, Wise Srl is a key technology provider to watch.

14. Qura: AI-Powered Preventative Health Intelligence

Qura is an Italian-founded AI preventative health platform that raised a €1.5 Million pre-seed round led by United Ventures in 2025. The platform targets patients with "persistent subclinical symptoms", conditions that fall below the threshold of acute illness but significantly impact quality of life.

Qura's strategy is to build an "EU-native" platform that is fully GDPR-compliant and medically validated. The funding is being used to expand the medical and engineering teams and to integrate the platform with local laboratory networks.

Strategic Priority	Action
Product Development	AI health intelligence for subclinical symptoms
Infrastructure	Integration with local laboratory networks
Compliance	GDPR-compliant and medically validated
Expansion	Preparation for European market entry

In an era where healthcare systems are shifting from reactive to proactive care models, Qura’s ability to leverage AI for preventative health screening makes it a highly relevant player for insurers and large-scale healthcare providers.

15. Corticale: The Next Frontier in Brain-Computer Interfaces (BCI)

Corticale is an Italian neurotechnology company specialising in the development of ultra-high-density, implantable neuroelectronic devices. Its BCIs are designed for both research and medical applications, including restoring communication for paralysed patients and assisting with prosthetic control.

The BCI market is entering a period of rapid acceleration, with the global market size projected to surpass $6 Billion by 2030. Major accelerators include improved neural decoding through AI and increased public funding through initiatives like the PNRR.

Corticale stands alongside international leaders like Neuralink and Synchron as a pioneer in minimally invasive implanted BCIs. The company represents Italy's most serious entry into the "brain-spine interface" sector, making it a critical watch for deep-tech venture capital and large-scale neurotech incumbents.

16. Angiodroid: Innovative CO2 Injectors and Heart Pumps

Angiodroid is a Bologna-based medtech company that has developed a proprietary CO2 injector device for peripheral angiography. This technology is a safer alternative to iodine-based contrast agents, which can cause complications in patients with kidney disease.

The company has raised approximately $10.2 Million in funding, including a Series B round in 2023 that saw participation from CDP Venture Capital and ALIAD (the venture capital arm of Air Liquide). Angiodroid’s presence in the heart pump device market, a sector estimated to be worth $10.84 Billion by 2034, adds another layer of strategic importance. Angiodroid is a prime example of a specialised Italian manufacturer that has successfully attracted corporate venture capital to fund its global expansion.

17. GreenBone Ortho: Biomimetic Bone Regeneration from Wood

GreenBone Ortho has developed a highly innovative bone regeneration therapy using biomimetic scaffolds derived from bamboo. The technology mimics the porous structure and chemical composition of human bone, facilitating the regeneration of tissue in large defects.

The bone graft substitutes market was valued at $4.29 Billion in 2025 and is projected to reach $7.64 Billion by 2034. GreenBone Ortho raised $8 Million in its Series B round and has reported excellent initial clinical results in patients.

Market Driver	Benefit of GreenBone Technology
Rising Orthopedic Surgeries	High-performance synthetic alternative
Biocompatibility Needs	Wood-derived scaffold mimics bone mineral phase
Risk of Donor Site Injury	Eliminates the need for autograft bone harvesting

The company is based in Faenza, Italy and is positioned as a high-growth player in the ortho-biologics sector.GreenBone's unique technology makes it an attractive acquisition candidate for a large orthopaedic company like Orthofix or Smith+Nephew looking to add "second-generation" synthetic substitutes to their portfolio.

18. Paginemediche: The Backbone of Italian Telemedicine Infrastructure

Paginemediche is a dominant force in Italy's digital healthcare landscape, serving as a primary provider of telemedicine and remote patient monitoring services. During the COVID-19 pandemic, the platform powered the national pre-triage and tele-monitoring services for infected patients, demonstrating its scalability and reliability.

The company operates within the framework of the National Recovery and Resilience Plan (PNRR), which allocates $1 Billion to telemedicine infrastructure through 2025. Paginemediche’s ability to integrate with various medical devices for chronic disease management, including cardiac and respiratory monitoring, positions it as the "digital front door" to community-based care in Italy.

As the Italian healthcare system undergoes a structural transition toward outpatient and home-based care, Paginemediche is a key infrastructure provider poised for further consolidation or large-scale strategic investment.

19. Patchai: Patient-Centric AI for Clinical Trials

Patchai, now an Alira Health company, developed an AI-powered virtual assistant specifically for patients in clinical trials. The platform is designed to improve patient adherence, engagement, and data quality by providing a more conversational and personalised experience for trial participants.

Founded in 2019 in Padua, Patchai represents the shift toward decentralized clinical trials (DCTs), a trend that has accelerated since the pandemic. By focusing on real-world evidence (RWE) generation and patient-reported outcomes (PROs), Patchai has built a platform that is essential for modern pharmaceutical R&D. Within the Alira Health ecosystem, Patchai continues to be a leader in the Italian digital health space, serving as a benchmark for how local AI startups can achieve high-value strategic exits.

20. KaiMed: Simplifying Surgical and Medical Treatments

KaiMed is a healthcare company dedicated to making medical treatments simpler, safer, and more accessible through innovative surgical solutions. Based in Italy, the company focuses on developing tools that help patients heal faster and streamline surgical workflows for clinicians.

While many companies in the Italian medtech space focus on high-complexity robotics, KaiMed addresses the "efficiency gap" in traditional surgery. Its focus on novel, easy-to-adopt solutions makes it a standard-bearer for the type of innovation that public health systems, strained by rising costs and aging populations, are increasingly prioritising.

Strategic M&A and Funding Outlook for 2026

The Italian healthtech and medtech market in 2026 is at an inflection point. The "analog" healthcare service sectors, such as dental and specialty clinics, are seeing intense "buy-and-build" activity from private equity firms looking for geographic arbitrage and operational efficiency. Simultaneously, "high-tech" sectors like surgical robotics and gene therapy are entering a consolidation phase where large strategics are acquiring innovation hubs to fill pipeline gaps.

The first half of 2025 saw a substantial spike in European healthcare M&A deal value, even as deal counts slightly decreased—a sign that investors are focusing on high-quality, proven assets. Italy, along with Spain, is viewed as the "Growth Frontier" of Southern Europe, offering the best opportunities for consolidation due to lower maturity in market concentration.

Key Investment Drivers for 2026:

Surgical Robotics Expansion: With the shift of surgery to ambulatory surgery centres (ASCs) to contain costs, modular and portable systems like those from MMI and CMR Surgical will be prioritised over the massive tele-operated systems of the past.
The Weight-Loss Tailwind: The obesity market, currently a $100+ Billion opportunity, will drive investment into "orthogonal" mechanisms like the miR-22 inhibition from Resalis Therapeutics.
Mental Health Consolidation: Regional leaders like Serenis will be targets for pan-European expansion as corporate wellness becomes a structural requirement for the modern workforce.
Infrastructure Interoperability: Startups that serve as the "translation layer" between legacy hospital systems and modern apps, the so-called "App Store for Hospitals", will be viewed as critical infrastructure.

The 20 companies identified in this report are not merely surviving; they are setting the pace for the digital transformation of European healthcare.

Their success in 2026 will be defined by their ability to navigate the complex regulatory moats of the EU and US while delivering clear, system-level value in a resource-constrained environment.

For strategic peers and professional investors, Italy represents one of the most compelling risk-adjusted entry points in the global healthtech and medtech landscape.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech